Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Telix Pharmaceuticals's annualized net income for the quarter that ended in Dec. 2025 was $-9.7 Mil. Telix Pharmaceuticals's average shareholder tangible equity for the quarter that ended in Dec. 2025 was $-169.8 Mil. Therefore, Telix Pharmaceuticals's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was N/A%.
The historical rank and industry rank for Telix Pharmaceuticals's Return-on-Tangible-Equity or its related term are showing as below:
During the past 11 years, Telix Pharmaceuticals's highest Return-on-Tangible-Equity was 55.59%. The lowest was -187.68%. And the median was -23.14%.
TLX's Return-on-Tangible-Equity is not ranked *
in the Biotechnology industry.
Industry Median: -42.435 * Ranked among companies with meaningful Return-on-Tangible-Equity only.
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Telix Pharmaceuticals Return-on-Tangible-Equity Related Terms
Telix Pharmaceuticals Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Telix Pharmaceuticals's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TLX vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Telix Pharmaceuticals's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Telix Pharmaceuticals Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Telix Pharmaceuticals's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Telix Pharmaceuticals's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 0.00% mean?
Telix Pharmaceuticals (TLX) has a Return-on-Tangible-Equity of 0.00% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Telix Pharmaceuticals and its competitors. According to the industry distribution chart, Telix Pharmaceuticals ranks #999999 out of 1200 companies in the Biotechnology industry.
Is Telix Pharmaceuticals' Return-on-Tangible-Equity too high?
Telix Pharmaceuticals' current Return-on-Tangible-Equity is 0.00%. Based on the distribution chart, Telix Pharmaceuticals ranks #999999 out of 1200 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Telix Pharmaceuticals has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Telix Pharmaceuticals' Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Telix Pharmaceuticals ranks #999999 out of 1200 companies for Return-on-Tangible-Equity. This places Telix Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Telix Pharmaceuticals and its competitors. Telix Pharmaceuticals's current Return-on-Tangible-Equity is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telix Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Telix Pharmaceuticals (TLX) is currently considered Possible Value Trap. The stock's GF Value™ is $29.37, compared to a current price of $11.84 — trading 59.7% below its estimated fair value. The current Return-on-Tangible-Equity is 0.00%. Telix Pharmaceuticals' overall GF Score™ is 50/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Telix Pharmaceuticals (TLX), the current Return-on-Tangible-Equity is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Telix Pharmaceuticals (TLX) Overvalued in 2026?
Based on GuruFocus' analysis, Telix Pharmaceuticals stock appears to be undervalued.
The current stock price of $11.84 is trading 59.7% below its estimated GF Value™ of $29.37.
GuruFocus considers Telix Pharmaceuticals to be Possible Value Trap.
Key valuation signals for TLX:
Return-on-Tangible-Equity: 0.00%
GF Value™: $29.37 vs. price of $11.84 (59.7% below fair value)
No single metric tells the full story. See the TLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
50GF Score
Get the complete analysis for TLX
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TLX has been successfully added to your 
